Roscovitine
>98%
- Product Code: 102379
CAS:
186692-46-6
| Molecular Weight: | 354.45 g./mol | Molecular Formula: | C₁₉H₂₆N₆O |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Roscovitine is primarily utilized in research settings to study cell cycle regulation and apoptosis due to its ability to inhibit cyclin-dependent kinases (CDKs). It has shown potential in cancer therapy by inducing cell cycle arrest and promoting apoptosis in tumor cells. Additionally, it is being explored for its neuroprotective effects in neurodegenerative diseases and its role in reducing inflammation in various conditions. Roscovitine is also investigated for its antiviral properties, particularly in inhibiting viral replication. Its applications extend to studying cellular processes and developing targeted therapies for diseases involving CDK dysregulation.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | White Solid |
| Purity (%) | 97.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | £67.62 |
+
-
|
| 0.010 | 10-20 days | £130.05 |
+
-
|
| 0.050 | 10-20 days | £344.23 |
+
-
|
| 0.100 | 10-20 days | £584.88 |
+
-
|
| 0.250 | 10-20 days | £986.10 |
+
-
|
Roscovitine
Roscovitine is primarily utilized in research settings to study cell cycle regulation and apoptosis due to its ability to inhibit cyclin-dependent kinases (CDKs). It has shown potential in cancer therapy by inducing cell cycle arrest and promoting apoptosis in tumor cells. Additionally, it is being explored for its neuroprotective effects in neurodegenerative diseases and its role in reducing inflammation in various conditions. Roscovitine is also investigated for its antiviral properties, particularly in inhibiting viral replication. Its applications extend to studying cellular processes and developing targeted therapies for diseases involving CDK dysregulation.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
£0.00
£0.00
Total :